key: cord-0967736-zu9olxm1 authors: Du, Richard; Tsougenis, Efstratios D.; Ho, Joshua W. K.; Chan, Joyce K. Y.; Chiu, Keith W. H.; Fang, Benjamin X. H.; Ng, Ming Yen; Leung, Siu-Ting; Lo, Christine S. Y.; Wong, Ho-Yuen F.; Lam, Hiu-Yin S.; Chiu, Long-Fung J.; So, Tiffany Y; Wong, Ka Tak; Wong, Yiu Chung I.; Yu, Kevin; Yeung, Yiu-Cheong; Chik, Thomas; Pang, Joanna W. K.; Wai, Abraham Ka-chung; Kuo, Michael D.; Lam, Tina P. W.; Khong, Pek-Lan; Cheung, Ngai-Tseung; Vardhanabhuti, Varut title: Machine learning application for the prediction of SARS-CoV-2 infection using blood tests and chest radiograph date: 2021-07-09 journal: Sci Rep DOI: 10.1038/s41598-021-93719-2 sha: 4b6c4892c90d7f27b8b51ffd0912d907f549c268 doc_id: 967736 cord_uid: zu9olxm1 Triaging and prioritising patients for RT-PCR test had been essential in the management of COVID-19 in resource-scarce countries. In this study, we applied machine learning (ML) to the task of detection of SARS-CoV-2 infection using basic laboratory markers. We performed the statistical analysis and trained an ML model on a retrospective cohort of 5148 patients from 24 hospitals in Hong Kong to classify COVID-19 and other aetiology of pneumonia. We validated the model on three temporal validation sets from different waves of infection in Hong Kong. For predicting SARS-CoV-2 infection, the ML model achieved high AUCs and specificity but low sensitivity in all three validation sets (AUC: 89.9–95.8%; Sensitivity: 55.5–77.8%; Specificity: 91.5–98.3%). When used in adjunction with radiologist interpretations of chest radiographs, the sensitivity was over 90% while keeping moderate specificity. Our study showed that machine learning model based on readily available laboratory markers could achieve high accuracy in predicting SARS-CoV-2 infection. Patient cohorts and analysis. Primary cohort. Summary of the study design and local outbreak timeline is presented in Fig. 1 . From the start of the local outbreak to 28th April 2020, a total of 85,393 patients from 32 hospitals in Hong Kong had taken the RT-PCR test for SARS-CoV-2 virus. After applying the inclusion and exclusion criteria, a total of 5230 patients were eligible and included in the primary cohort. Of the 5230 patients, 18 (0.3%) patients were co-infected with COVID-19 and bacterial pneumonia, 15 (0.3%) patients were co-infected with COVID-19 and another viral infection, 48 (0.9%) patients were co-infected with bacterial and non-COVID-19 viral pneumonia, and one patient was coinfected with all three. Due to the low amount of cases, the coinfected cases were removed from further analysis (n = 82). The primary cohort then finally included a total of 5148 patients. Of these, 447 patients were COVID-19 (8.7%), 405 patients (7.9%) with other viral pneumonia, and 1515 patients (29.4%) with bacterial pneumonia. A total of 1,862 (36.2%) were classified as clinical pneumonia with no laboratory confirmation or incomplete tests. For the non-pneumonia patient, there were 919 patients (17.96%), of whom 256 (5.0%) were classified with other (non-pneumonia) infections by ICD-9 classification. Baseline characteristics of the primary cohort with laboratory tests and differences between disease groups are described in Table 1 . There were significant differences between patient age across disease groups (Kruskal-Wallis H: p < 0.001). Patients with COVID-19 were the youngest and were significantly younger than other viral (Mann-Whitney: p < 0.001) and bacterial pneumonia (Mann-Whitney: p < 0.001). Box plots describing the distribution of the laboratory blood markers are presented in Fig. 2 . WBC was significantly lower in patients with COVID-19 than any other disease groups with large estimated effect sizes (f = 0.78 to 0.86). CRP and LDH were also found to be statistically lower in COVID-19 patients compared to other groups except for other non-pneumonia infections. In contrast, WBC, CRP and LDH were found to be highest in bacterial pneumonia. Correlation between each laboratory markers and age was analysed. Neutrophils count was found to be highly positively correlated with WBC (r s = 0.96; p < 0.001). In addition, monocytes and WBC were found to be moderately correlated (r s = 0.53; p < 0.001). Haemoglobin were also found to be highly correlated with haematocrit (r s = 0.98; p < 0.001), and moderately correlated with age (r s = 0.45; p < 0.001). No other features were found to be moderately or strongly correlated with age (r s = -0.30 to 0.28). Validation cohorts. To evaluate the performance of the discriminative model, three validation cohorts across different periods of the epidemic in Hong Kong were obtained. Baseline demographics and clinical characteristics comparing COVID-19 and non-COVID-19 patients in the validation sets are presented in Table 2 . A total of 605 patients were obtained for validation set 1, of whom 40 patients were positive for COVID-19. A subset of patients in validation set 1 that fulfilled the criteria for the primary cohort was obtained to test the performance of the model for detecting other subtypes of pneumonia. Distribution of laboratory markers between subtypes of pneumonia of the validation set 1 are given in Supplementary Table 1 . Validation set 2 and 3 were consecutive temporal validation sets based on patients that falls outside period of the primary cohort. As the time of the validation set 2 and 3 was outside of influenza season, many of the patients were only tested for a subset of common viruses (Viral group 1 in Supplementary Fig. 1 Given the significant differences in age between groups, to avoid bias, age and haemoglobin were not used for the model. In addition, monocytes, neutrophils and haematocrit were also removed for redundancy. The features selected for the final model were sex, WBC, lymphocytes, platelets, CRP and LDH. Several algorithms and classifiers were considered (see Supplementary Table 3 ). Categorical gradient boosting (CatBoost) was selected as the classifier of the model due to the ease of handling missing numbers and categorical features, and also produce the highest cross-validation performance. The CatBoost model was trained with 80% of the training set with the other 20% used for cross-validation, model selection, and threshold selection. Model evaluation. The performance of the ML model was validated on three validation sets. In addition, a clinical model was devised to provide baseline performance for the evaluation, along with radiologist interpreta- Mean ± SD 0.5 ± 0. Missing, n (%) Missing, n (%) 0 (0) 0 (0) 6 (4) 119 (4) 1 (4) 5 (1) Mean ± SD 6.7 ± 2.4 10.7 ± 6.0 5.3 ± 1.7 10.3 ± 6.0 5.0 ± 1.5 10.6 ± 5.7 Median (IQR) 6.2 (5.1-8.0) 9.2 (6.7-13.0) 5.0 (4.1-6.2) 9.0 (6.6-12.5) 4.7 (3.9-6.0) 9.4 (7.0-13.0) Monocyte 10 Table 4 . The validation of all models in classifying COVID-19 is summarised in Table 3 . For discriminating COVID-19, the ML model achieved high AUCs and specificity in all three validation sets (AUC > 0.9 and specificity > 0.9). Radiologists' read achieved low sensitivity, and moderate to high specificity in the validation set 1 and set 3. When used together, the combined ML model and radiologists achieved a significantly higher sensitivity of over 90% in each validation sets but a reduction in specificity. The basic clinical model was not able to accurately identify COVID-19 patients. Performance of the model on the classification of other pneumonia subtypes in the validation set 1 is presented in Table 4 . The model achieved a moderately high AUC of 77.4% in classifying bacterial pneumonia but was unable to adequately discriminate between other viral and non-pneumonia patients. The SHAP analysis of the models shows that WBC was the most important predictor for COVID-19 with a decrease in WBC corresponding with a higher probability of COVID-19. For bacterial pneumonia, WBC and lymphocytes have the highest impact, with high WBC and low lymphocytes count corresponding to an increase in the likelihood of bacterial pneumonia. Summary plots for SHAP analysis and illustrative examples of how the www.nature.com/scientificreports/ final prediction using the combined model works in practice with the contribution of SHAP value are shown in Fig. 3 and supplementary Fig. 2 . There has been an emphasis on testing using RT-PCR in the early stages of management of the COVID-19 pandemic. Despite the growing availability of RT-PCR testing kits, confirmation is usually only available after triaging, or treatment decisions have been made. Leveraging existing infrastructures and differentiating from other common respiratory tract infections need to be considered for long term sustainability in combating the disease. There are two potential scenarios when using simple tests may be useful. First, a model may be helpful in countries that cannot afford large supplies of RT-PCR testing kits, particularly currently it is looking likely that the pandemic will assume a more protracted course with prolonged economic impact. Given the high sensitivity and negative predictive value of our combined model, it is potentially indicated for low-risk patient stratification, whereby a negative prediction from the ML model allows for patients' discharge while awaiting final laboratory confirmation. The risk of subsequent community infection is thus minimised whilst not overburdening the healthcare system or isolation centres. Second, consider a scenario whereby the disease prevalence is low or becomes seasonal; the model may serve as a surveillance system for future outbreaks. The machine learning approach offers the potential of automation with tasks running in the background and only alerting clinicians in case of positive prediction. The tools being used here are based on clinical intuition. Using laboratory blood results for screening is already being done in clinical practice even at the early stages of the outbreak 16 . CXR radiographic appearances, although overlaps with other viral aetiologies 17 , when used in combination with blood test increases sensitivity. Machine learning has the potential to better handle non-linearly separable data thus achieving better performance. Despite that, analysis of our machine learning model had found linear association in some predictor such as WBC and CRP. WBC was significantly lower in COVID-19 patients than viral pneumonia patients, but the median value was still within the normal range. Human interpretation which relies solely on just the reference range may miss this subtlety. Major strengths in our study include a large sample size of patients with reference laboratory testing in all cases, in a population where there was clinical suspicion of respiratory infection at the initial presentation. Our cohorts of positive COVID-19 cases were also consecutive during different phases of outbreaks in Hong Kong. The study also involved 27 hospitals in all territories of Hong Kong and was validated on three separate heldout test sets, with the latter two validation sets included consecutive patients during the third wave of infection. We also only used blood results and CXR at the initial presentation, which mirrors the potential use case. The COVID-19 cases in Hong Kong are unique as all the patients regardless of clinical severity were hospitalised. Our model is therefore likely applicable to patients with full disease spectrum. Several recent studies have been published on COVID-19, but in the initial periods, these have mainly included clinical characteristics, laboratory findings, descriptive findings of radiological appearances and were mostly focusing on COVID-19 patients in isolation [5] [6] [7] . Our findings were broadly in line with previous studies with low white cell count and CRP having high discriminability. Of note, whilst the median lymphocyte count in our cohorts was low for COVID-19, it was similar to other viral pneumonia. It is known that other viral pneumonias were also associated with lymphopenia 8, 18 . Moreover, the median value for non-pneumonia was even lower thus limiting its discriminating power. CRP in our cohort was raised but not as high compared to other pneumonia. Owing to different reference ranges, the actual values are not directly comparable with other studies. The findings may also reflect the range of clinical spectrum at presentations where our patients may present at an earlier stage compared to at the epicentre of the outbreak in other countries. Our CRP results are similar to one other territory-wide study that was performed in Hong Kong 19 and another smaller study from Taiwan 20 , which directly compared laboratory markers with other non-COVID-19 respiratory infections. This was also true in early-stage patients in a separate study 21 , as well as in one of the largest cohort to date which included severity of clinical status, where the CRP was higher in more severe groups reflecting more severe inflammatory states 5 . A few recent studies demonstrated the value in using data-driven machine learning approach in prognostication for COVID-19 22, 23 , and have similarly identified lymphocytes and CRP to be important features, as well as LDH for predicting mortality. In terms of diagnostic capability with machine learning, some recent studies have also been performed, but with smaller datasets, lack of temporal validation and often without clinical comparison [24] [25] [26] . More recently several machine learning based approaches have been published demonstrating more broader applicability in COVID-19 related applications including triage assessment 27 , severity classifcaiton 28, 29 , risk prognostication including mortality 30 as well as applying to multi-omics data 31 . For example, a similar approach was tried with similar findings also with an attempt for explanability similar to our study 32 . This study used decision trees and criteria graph whilst our study used SHAP analysis. Another recently published study also applied www.nature.com/scientificreports/ machine learning to clinical and laboratory improves the performance of the prediction of COVID-19 33 . There is increasing body of evidence in the literatures now supporting the potential usefulness in applying machine learning for these tasks. Some limitations are worth noting. First, this is a retrospective study. Prospective validation of such models would be helpful to see how it performs in real practice. Second, there are potentially important features such as other laboratory and clinical features which were not used. Owing to the retrospective nature of this study, other blood tests were fewer in numbers in our cohorts. Clinical notes at the initial presentation were in hand-written formats and were not readily retrievable at scale across multiple hospitals for all patients. However, we were able to review these for validation sets 1 and 3. In particular, the duration of clinical symptoms may be helpful to include in future models as these may show better discriminability between seasonal influenza. Thirdly, the generalisability of the model needs to be tested in other settings. The sensitivity of any diagnostic test depends on patient characteristics. More specifically, predictive models are derived from the training datasets with its own distribution of disease severity and varying disease spectrum. In Hong Kong, all patients are admitted to hospitals or treatment centres regardless of their clinical status. Different countries have different approaches to testing and hospitalisation of patients with COVID-19, so the generalisability will depend on how well this matches with the idiosyncrasies of the individual healthcare practices. In summary, a machine learning model was able to achieve high accuracy for the prediction of SARS-CoV-2 infection. Adjunctive use of chest radiograph could play a role in increasing sensitivity while achieving moderate specificity when combined with ML blood model, which may have potential implications in triaging patients, particularly when RT-PCR testing resources are scarce. Ethics approval. This study protocol was approved by multi-institutional review boards in multiple hos- Due to a large number of patients who were screened because of cross-border travel or close contact with positive patients, to select symptomatic patients from the cohort, the following inclusion criteria were applied: (i) had frontal chest radiographs on the date of the RT-PCR test, (ii) had laboratory testing done, specifically haematological blood count with or without differential counts, C-reactive protein (CRP) and lactate dehydrogenase (LDH) on the date of the RT-PCR test. In addition to test results, the patient demographics and ICD diagnosis code at the date of the first examination of each patient were also retrieved. Patients younger than 16 years old were excluded. Primary cohort. The primary cohort consists of patients in the first and second wave of infection from 1st January to 28th April 2020. To analyse the distribution of laboratory markers for different aetiology of pneumonia, patients that had nasopharyngeal aspirate (NPA) virologic sampling tested for common respiratory pathogens using multiplex PCR with or without sputum culture were selected. Patients were categorised into the following six disease groups: COVID-19, other viral pneumonia, bacterial pneumonia, clinical pneumonia, other infection, and other diseases. For patients included in COVID-19, other viral and bacterial pneumonia groups, they must be laboratory-confirmed positive by their respective laboratory tests. Viral and bacterial pneumonia is confirmed by either PCR or sputum culture. Patients that have partial laboratory tests or negative laboratory test results but has an ICD-9 classification of pneumonia were a group as clinical pneumonia. For other infection and disease, to ensure the patient does not have pneumonia pathogens, patient included to the groups must have negative test results for RT-PCR for SARS-CoV-2 and other common viral pathogens and sputum culture for bacterial infection. A detailed summary for cohort selects and lists of pathogens tested by PCR are listed in Supplementary Fig. 1 . To evaluate the performance of the modelling in discriminating the disease groups, the model was tested on three different validation cohorts across different time periods during the epidemics in Hong Kong. The first validation cohort (validation set 1) consisted of all COVID-19 patients presented in Hong Kong between 16th February to 2nd March with patients from 21 different hospitals. Negative patients for the validation set 1 were randomly sampled in the same period to give approximately 6% prevalence. To assess the generalisability of the findings, the second and third validation cohorts were obtained between 20th to 31st July 2020, which coincided with the third wave of local outbreak in Hong Kong. The second validation cohort (validation set 2) consisted of consecutive suspected patients presented across Hong Kong in 27 hospitals over 4 days www.nature.com/scientificreports/ between 20th to 23rd July, and the third validation cohort (validation set 3) was based on consecutive patients at a single hospital (XX Hospital) between 24th to 31st July. For validation set 1 and 3, in addition to laboratory test results, clinical details and frontal chest radiographs were also retrieved for analysis. Clinical details included travel or contact history, patient condition and symptoms at presentation, and were obtained from reviewing patient admission notes or discharge summaries. Statistical analysis. The patient demographics and the blood test results for haemoglobin, haematocrit, white blood cells (WBC), neutrophils, lymphocytes, monocytes, platelets, CRP and LDH were recorded and analysed for each disease group. For each variable, normality was tested by Shapiro-Wilks test. Comparison across diseases groups was tested by Kruskal-Wallis H test, with post hoc Mann-Whitney U test for statistical difference between individual groups. The effect size of laboratory markers between each group was estimated by the common language effect size f. f is equivalent to the area under the curve (AUC) for the receiver operating characteristic curve (ROC). Correlation between each test marker and age were also analysed by Spearman's rank correlation coefficient r s . To analyse the discriminability of the laboratory markers, the features were modelled by machine learning to classify whether the patient has COVID-19, other viral pneumonia, bacterial pneumonia or non-pneumonia. The training set for the model was based on the patients from the primary cohort with overlapping patients from the validation sets removed. Patients that were classified as clinical pneumonia were not included in the modelling. The model was evaluated in the three validation sets to assess the performance and generalisability. In addition to the machine learning model (ML), the performance was compared with a clinical model and radiologist reads of frontal chest radiographs to provide a baseline for evaluation. Clinical model. A clinical model based on the blood test was devised. The model is based on the early observation that lymphopenia associated with COVID-19. Local diagnostic ranges for lymphocytes were used for the model. A patient is classified as likely to have COVID-19 if the patient has a lymphocytes count of less than 3.89 × 109/L and at least one of the following condition: (a) had close contact with a confirmed case, (b) had a travel history to an affected area classified as having active infections (e.g. mainland China, Europe and the US), (c) presented with fever (temperature > 37.5 °C), (4) required supplemental oxygen on admission. Radiologist interpretation and combined radiologist ML model. A pre-defined set of CXR findings were used based on local experience and emerging literature to define "typical" radiographic features of COVID-19 13, 17 . Radiologist interpretation of the frontal chest radiographs was performed on the validation set 1 and validation set 3. For validation set 1, four board-certified radiologists (2, 5, 10, and 15 years of experience) with subspecialty training in thoracic radiology read the films independently and blinded of RT-PCR results. The consensus agreement was used as the reference standard if two or more radiologists agreed on the finding. If there was a two-way tie, i.e. two radiologists reported positive finding, and two radiologists reported negative results, then the final prediction will be positive. This is because the aim is to increase sensitivity. For validation set 3, only one radiologist with thoracic radiologist read the films. As most confirmed patients were admitted to hospital and owing to extensive testing and contact tracing, it is thought that a lot of patients were at the early stages of the disease. Chest radiographs may be normal, or if changes were present, they might be too subtle to be detectable. Hence, radiologist interpretation of chest radiographs alone will be unlikely to achieve very high sensitivity in detecting COVID-19. In order to maximise sensitivity for a combined ML model, the prediction of the model is deemed positive if either the ML model or radiologist reads positive (please refer to Supplementary Document for more details). Evaluation. The AUC, accuracy, sensitivity, specificity, positive prediction value (PPV), and negative prediction value (NPV) were calculated for the prediction of each model. 95% confidence intervals (CI) for accuracy, sensitivity, and specificity were calculated using Clopper-Pearson "exact" methods 37 . Standard logit methods and Delong methods were used to estimate the CI for the predictive values and AUC, respectively 38, 39 . In addition to the performances of the model, feature importance and interaction were analysed by using post-model Shapley additive explanations (SHAP) analysis 40 Due to the retrospective nature of the study, specific patient level data used for this study cannot be made publicly available as patients did not agree for their data to be shared publicly. De-identified data may be available upon reasonable request. Received: 10 October 2020; Accepted: 21 June 2021 Variation in false negative rate of RT-PCR based SARS-CoV-2 tests by time since exposure False-negative results of initial RT-PCR assays for COVID-19: A systematic review. medRxiv 2020 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study Characteristics of coronavirus disease 2019 in China Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China The diagnostic and prognostic significance of relative lymphopenia in adult patients with influenza A Comparative analysis of the host response to community-acquired and hospital-acquired pneumonia in critically ill patients Clinical features of patients infected with 2019 novel coronavirus in Wuhan Detection of COVID-19 infection from routine blood exams with machine learning: A feasibility study Machine learning-based prediction of COVID-19 diagnosis based on symptoms Imaging profile of the COVID-19 infection: Radiologic findings and literature review Frequency and distribution of chest radiographic findings in COVID-19 positive patients Radiology Decision Tool for Suspected COVID-19 Lessons from the Frontline of the COVID-19 Outbreak Frequency and distribution of chest radiographic findings in COVID-19 positive patients Diagnostic importance of relative lymphopenia as a marker of swine influenza (H1N1) in adults Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19 Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study An interpretable mortality prediction model for COVID-19 patients Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19 COVID-19 diagnosis by routine blood tests using machine learning Rapid and accurate identification of COVID-19 infection through machine learning based on clinical available blood test results. medRxiv 2020 Use of machine learning and artificial Intelligence to predict SARS-CoV-2 infection from full blood counts in a population Development and validation of a prognostic COVID-19 severity assessment (COSA) score and machine learning models for patient triage at a tertiary hospital Machine learning based predictors for COVID-19 disease severity Correlation between lung infection severity and clinical laboratory indicators in patients with COVID-19: A crosssectional study based on machine learning Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients Accurate classification of COVID-19 patients with different severity via machine learning Explaining machine learning based diagnosis of COVID-19 from routine blood tests with decision trees and criteria graphs Machine learning is the key to diagnose COVID-19: A proof-of-concept study Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement Advances in Neural Information Processing Systems CatBoost for big data: An interdisciplinary review The use of confidence or fiducial limits illustrated in the case of the binomial Confidence intervals for predictive values with an emphasis to case-control studies Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach Explainable machine-learning predictions for the prevention of hypoxaemia during surgery model development, data analysis, data interpretation, figures production, editing/writing manuscript. E.D.T.: study design, data collection, data analysis, data interpretation, editing/writing manuscript. J.K.Y.C.: study design, data collection, data analysis, data interpretation, editing/writing manuscript study design, data analysis, data interpretation, editing/writing manuscript. M.Y.N.: literature review, study design, data analysis, data interpretation, editing/writing manuscript. S.T.L.: data analysis, data interpretation, editing/writing manuscript. C.S.Y.L.: data analysis, data interpretation, radiographic interpretation, editing/ writing manuscript data analysis, data interpretation, editing/writing manuscript. Y.C.I.W.: data analysis, data interpretation, editing/writing manuscript. K.Y.: data analysis, data interpretation, editing/ writing manuscript. Y.C.Y.: data analysis, data interpretation, editing/writing manuscript. T.C.: data analysis, data interpretation, editing/writing manuscript study design, project formulation, data collection, data interpretation, editing/writing manuscript. V.V.: literature review, study design, data collection, radiographic interpretation, model development, data analysis, data interpretation The authors declare no competing interests. Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-93719-2.Correspondence and requests for materials should be addressed to V.V.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.